PSYCHIATRY AND CLINICAL NEUROSCIENCES is a leading journal in the fields of psychiatry and clinical neurology, published by Wiley. With a commendable impact factor and a position within the prestigious Q1 quartile across multiple relevant categories—including Medicine (Miscellaneous), Neurology, and Psychiatry and Mental Health—this journal stands out for its rigorous peer-reviewed content that addresses critical issues in mental health and neurological disorders. Established in 1933, the journal has a rich history of contributing impactful research that guides both clinical practice and academic inquiry. Although it is not an open-access journal, its high relevance is underscored by its Scopus rankings, with notable percentiles in Psychiatry and Neurology, making it a vital resource for researchers, clinicians, and students looking to stay abreast of the latest advancements. Located in the United Kingdom, PSYCHIATRY AND CLINICAL NEUROSCIENCES aims to bridge the gap between theory and practical application, fostering a comprehensive understanding of the complex interplay between mental health and neurological conditions.

The JOURNAL OF CLINICAL PSYCHIATRY is a premier publication dedicated to advancing the understanding and treatment of psychiatric disorders. Established in 1978 and published by Physicians Postgraduate Press, this esteemed journal provides a vital platform for researchers, clinicians, and mental health professionals to share innovative findings and evidence-based practices in psychiatry. With an impressive impact factor and recognized as a Q1 journal in both Medicine (miscellaneous) and Psychiatry and Mental Health, the journal ranks among the top in its field, sitting at 96th out of 567 in Scopus rankings, placing it in the 83rd percentile. The journal's commitment to high-quality, peer-reviewed articles facilitates the dissemination of knowledge crucial for advancing clinical practices and improving patient outcomes. Access to its latest research is offered through institutional subscriptions, making it an essential resource for anyone involved in the mental health sector, from seasoned practitioners to aspiring students.

General Psychiatry is a leading open-access journal published by BMJ PUBLISHING GROUP, dedicated to advancing the field of psychiatry and mental health. With an impressive impact factor and ranked in the Q1 category across various related disciplines—including Psychiatry and Mental Health, as well as Clinical Neurology—this journal offers a vital platform for researchers and practitioners in the field to disseminate high-quality studies and insights. The journal has been open access since 2018, ensuring that the latest research is freely available to a global audience, thus fostering greater collaboration and innovation. With a focus on significant developments and emerging trends, General Psychiatry serves as an essential resource for professionals keen on improving mental health practices and understanding neurological aspects of mental disorders. The journal is based in the United Kingdom, reflecting a commitment to global health discussions and initiatives in psychiatry.

EUROPEAN PSYCHIATRY, published by Cambridge University Press, stands at the forefront of advancements in the field of psychiatry and mental health, serving as a vital resource for researchers, professionals, and students alike. With an impressive Q1 ranking in Psychiatry and Mental Health and an impact factor that underscores its significance, this journal fosters innovative studies and discussions that shape contemporary understanding of mental health issues. Offering Open Access since 2020, it ensures that high-quality research is readily available to a global audience, bridging gaps in knowledge dissemination. The journal, which has been publishing since 1991, encompasses a broad range of topics relevant to mental health, emphasizing evidence-based practices and interdisciplinary approaches to treatment and care. With its ongoing commitment to excellence, EUROPEAN PSYCHIATRY continues to be an indispensable platform for advancing the science of mental health.

Epilepsy & Behavior Reports, a distinguished journal published by ELSEVIER SCIENCE INC, specializes in the latest research and developments in the field of epilepsy and related behavioral conditions. Since its inception in 2019 as a fully Open Access journal, it has carved a niche for itself within the scientific community, providing an essential platform for researchers and clinicians focused on behavioral neuroscience and neurology. The journal's commitment to disseminating high-quality research is reflected in its current rankings within Scopus, placing it within the Q3 category for Behavioral Neuroscience and Clinical Neurology, underscoring its relevance to emerging trends in these fields. Located in the heart of New York, the journal strives to foster collaboration and innovation, making it a vital resource for academics, practitioners, and students eager to advance their understanding of epilepsy and its behavioral implications. The convergence of expertise and research in Epilepsy & Behavior Reports promises to illuminate crucial aspects of neurological health, driving forward the discourse that shapes future treatment and understanding of epilepsy.

INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE is a distinguished publication in the field of Psychiatry and Mental Health, published by TAYLOR & FRANCIS LTD in the United Kingdom. With an impressive 2023 impact factor that places it in the Q2 category among its peers, this journal is an essential resource for researchers, clinicians, and students dedicated to advancing mental health practices and understanding psychiatric disorders. Covering topics from clinical studies to innovative treatment methodologies, the journal welcomes original research, reviews, and case studies that contribute valuable insights into clinical practice. Accessible without any open access restrictions, the journal has been a pivotal platform since its inception in 1997, facilitating knowledge exchange in the field up to 2024. As evidenced by its notable Scopus ranking within the top 73rd percentile of Psychiatry and Mental Health, it remains committed to impacting clinical practices significantly.

Schizophrenia Research is a premier academic journal focused on innovative research within the domain of psychiatry and mental health, published by Elsevier. With its ISSN 0920-9964 and E-ISSN 1573-2509, the journal has established a strong presence since its inception in 1988, evolving to publish cutting-edge findings up to 2024. Positioned in Q1 in Psychiatry and Mental Health and Q2 in Biological Psychiatry, it ranks impressively in the 83rd percentile among its peers, according to Scopus, ranking #93/567 in the field of Medicine, and #12/51 in Neuroscience. This journal serves as a vital platform for the dissemination of significant scientific advancements and theoretical insights into schizophrenia, fostering a deeper understanding of mental illnesses. Although it operates on a subscription basis, its critical role in informing both ongoing research and clinical practices cannot be overstated, making it an essential resource for researchers, clinicians, and students alike. Join a global community dedicated to improving mental health outcomes and advancing the study of schizophrenia through this reputable publication.

NEUROPSYCHOPHARMACOLOGY is a prestigious academic journal dedicated to advancing our understanding of the intricate relationship between psychiatric disorders and pharmacological treatments. Published by SpringerNature in the United Kingdom, this leading journal has been a cornerstone in the field since its inception in 1987, with a converged publication timeline extending to 2024. With a remarkable impact factor and illustrious rankings—being positioned 19th in Psychiatry and Mental Health and 16th in Pharmacology—NEUROPSYCHOPHARMACOLOGY is recognized for its rigorous peer-reviewed research that informs clinical practice and enhances therapeutic interventions. The journal is classified in Q1 quartile categories for both Pharmacology and Psychiatry and Mental Health, highlighting its commitment to excellence. Researchers, professionals, and students are encouraged to contribute to this vital dialogue, as the journal does not currently offer open access, emphasizing the importance of curated, high-quality content. By publishing innovative studies and reviews, NEUROPSYCHOPHARMACOLOGY plays a crucial role in shaping the future of mental health treatments and understanding neurobiological mechanisms, making it an indispensable resource for those at the forefront of psychiatric research.

Frontiers in Psychiatry is a leading journal dedicated to advancing research within the field of psychiatry and mental health. Published by FRONTIERS MEDIA SA, the journal has established a commendable reputation since its inception, reflected in its Q1 status in the 2023 Psychiatry and Mental Health category and a robust ranking of 142 out of 567 in the Scopus database. With an open access model initiated in 2009, Frontiers in Psychiatry aims to disseminate high-quality research to a global audience, fostering collaboration and innovation among researchers, clinicians, and students alike. The journal covers a broad spectrum of topics, including neurobiology, psychosocial factors, treatments, and public health implications of mental disorders, ensuring comprehensive representation of contemporary psychiatric science. Located in Lausanne, Switzerland, and running until 2024, the journal not only emphasizes the importance of mental health research but also encourages interdisciplinary discourse, making it an essential resource for anyone invested in the well-being of individuals and communities alike.

Biological Psychiatry is a premier journal dedicated to advancing the understanding of the biological underpinnings of psychiatric disorders. Published by Elsevier Science Inc, this esteemed journal is recognized globally for its rigorous peer-reviewed research and contributes significantly to the field of biological psychiatry. With an impressive impact factor that places it in Q1 of its category and ranks 3rd out of 51 in Neuroscience Biological Psychiatry, it reflects the journal's strength in disseminating high-quality findings that push the boundaries of knowledge. Since its inception in 1969, the journal has undergone continuous evolution, aiming to integrate biological and clinical perspectives to optimize the understanding of mental health conditions. Although it does not offer open access, Biological Psychiatry serves as a critical resource for researchers, practitioners, and students, offering insights that influence both theoretical frameworks and practical applications in the realm of psychiatric science.